Press release
Diffuse Large B-cell Lymphoma Therapeutics Market 2024-2033: Trends, Growth & Analysis
The diffuse large b-cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.49 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to biomarker discovery, immunotherapy advancements, rising incidence rates, global aging population, healthcare infrastructure development, expanded access to novel drugs.. Major trends in the forecast period include rise of outpatient treatment settings, collaborative clinical trials, patient-centric care models, advances in diagnostic imaging, healthcare digitalization..
Market Overview -
Diffuse large B-cell lymphoma therapeutics refer to the treatment approaches and medications used to manage and combat diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma characterized by rapidly growing cancerous B-cells.
Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10805&type=smp
Rising Prevalence Of Diffuse Large B-Cell Lymphoma To Drive Market Growth
The increasing incidence of diffuse large B-cell lymphoma (DLBCL) is expected to propel the growth of the diffuse large B-cell lymphoma therapeutics market going forward. Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive cancer that originates from B-cells in the lymphatic system and is characterized by rapid and diffuse growth. It is a type of non-Hodgkin lymphoma (NHL). The diffuse large B-cell lymphoma therapeutics help to improve outcomes for individuals already diagnosed with the condition by targeting and managing the cancer cells. For instance, the American Cancer Society, a US-based voluntary health organization, estimated that in 2023, about 80,550 people (44,880 males and 35,670 females) will be diagnosed with non-Hodgkin's lymphoma (NHL), where about 20,180 people will die from NHL. Therefore, the increasing incidence of diffuse large B-cell lymphoma (DLBCL) drives the growth of the diffuse large B-cell lymphoma therapeutics market.
Competitive Landscape -
Major companies operating in the diffuse large b-cell lymphoma therapeutics market report are Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Erytech Pharma SA, Xencor Inc., Denovo Biopharma LLC, Calithera Biosciences Inc., IMV Inc., Biogen Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG,
Advancements In Drug Therapeutics Transforming The Market
Development drug therapeutics are a key trend gaining popularity in the diffuse large B-cell lymphoma therapeutics market. Major companies operating in the diffuse large B-cell lymphoma therapeutics market are developing drugs for therapies to sustain their position in the market. For instance, in June 2022, Bristol-Myers Squibb, a US-based pharmaceutical company focused on research and development of drugs, received US FDA approval for CAR T Cell Therapy Breyanzi for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed or refractory large B-cell lymphoma. Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for a broad range of patients having primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B.
Browse Full Report @
https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report
Key Segments -
The diffuse large b-cell lymphoma therapeutics market covered in this report is segmented -
1) By Drug Class: Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
3) By Route of Administration: Oral, Parenteral, Other Routes
4) By End User: Hospitals, Clinics, Other End-Users
Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diffuse Large B-cell Lymphoma Therapeutics Market 2024-2033: Trends, Growth & Analysis here
News-ID: 3477736 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Therapeutics
Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.
DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years.
DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,…
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611
Focused on growth…
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.
Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hodgkin's…
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.
Key Takeaways from…
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant…
